Online citations, reference lists, and bibliographies.
← Back to Search

New Strategies For Polymer Development In Pharmaceutical Science — A Short Review

A. Godwin, K. Bolina, M.-Cl. Clochard, E. Dinand, S. Rankin, S. Simic, S. Brocchini
Published 2001 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
We are developing synthetic polymers for pharmaceutical and medical applications. These applications can be broadly grouped on how the polymer will be utilized e.g. material, excipient or molecule. Our focus is to develop polymers with more defined structures that are based on biological, physicochemical and/or materials criteria. Strategies are being developed to more efficiently optimize structure—property correlations during preclinical development. We describe two examples of our research on pharmaceutical polymer development: narrow molecular weight distribution (MWD) homopolymeric precursors which can be functionalized to give families of narrow MWD homo‐ and co‐polymers, and hydrolytically degradable polymers.
This paper references
Amino acid derived polymers
A. Nathan (1994)
Polymer therapeutics for tumour specific
R. Duncan (1997)
Effect of the chemicalmodificationof dextran on the degradation by dextran - ases
J. Vercauteren (1990)
10.1016/S0169-409X(96)00403-6
Pharmacokinetic evaluation of polymeric carriers
M. Nishikawa (1996)
10.1002/MACP.1993.021940201
Esterification and amidation of polymeric acyl chlorides. A new route to polymethacrylates and polymethacrylamides with a variety of different side groups
P. Strohriegl (1993)
10.1016/S0939-6411(00)00075-8
HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action.
J. Kopeček (2000)
10.1016/0277-5379(91)91369-T
Preclinical evaluation of polymer-bound doxorubicin
R. Duncan (1991)
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
P. Vasey (1999)
10.1126/SCIENCE.3484557
Specific immunosuppression by immunotoxins containing daunomycin.
E. Diener (1986)
Synthesis of soluble polymers formedicine that degradeby intramolecular acid catalysis. Macromol
M. Clochard (2000)
10.1038/37084
Facile synthesis of block copolypeptides of defined architecture
T. Deming (1997)
10.1016/0006-2952(74)90174-9
Commentary. Lysosomotropic agents.
C. de Duve (1974)
The uses and properties of PEG-linked proteins.
C. Delgado (1992)
10.1021/BC970184F
Stabilization of substances in circulation.
C. Monfardini (1998)
10.1021/JM00085A012
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates and drug-spacer derivatives and their catabolism in renal cortex homogenates and lysosomal lysates.
E. Franssen (1992)
10.1039/P29720001206
Structure and efficiency in intramolecular and enzymic catalysis. Catalysis of amide hydrolysis by the carboxy-group of substituted maleamic acids
A. Kirby (1972)
Synthesis and biological evaluation of immunoconjugates of adriamycin and human IgM linked by poly
C Hoes (1996)
10.1007/BFB0027551
Poly(Ortho Esters)
J. Heller (1993)
Synthesis of soluble polymers designed to degrade by intramolecular acid catalysis
Mcd Clochard (2000)
10.1073/PNAS.95.8.4607
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.
S. Hobbs (1998)
10.1007/3540587888_14
Polymer conjugates with anticancer activity
D. Putnam (1995)
10.1007/978-3-642-65146-5_16
CHEMICAL RADIOPROTECTION WITH N- AND S-CONTAINING POLYMERS.
H. Ringsdorf (1971)
SYNTHESIS OF A POLYMERIC PRECURSOR BY ATRP FOR CONVERSION TO POLYMER-DRUG CONJUGATES
A. Godwin (2000)
10.1054/bjoc.1999.1171
Vascular permeability in a human tumour xenograft: molecular charge dependence
M. Dellian (2000)
10.1385/0-89603-268-X:311
Chemical modification of proteins.
A. Carne (1994)
Synthetic polyanions: molecular weight, macrophage activation and immunologic response
W. Regelson (1974)
10.1016/0959-8049(94)00514-6
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier.
L. Seymour (1995)
Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Chun Xing Li (1998)
Living radical polymerizations
O. Igaku Shion (1996)
Polymer drug conjugates : drug release from pendent linkers
S. Brocchini (1999)
Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug–protein conjugates and drug-space derivatives and their catabolism in renal cortex homogenates and lysosomal
E. Franssen (1992)
Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug.
R. Dillman (1988)
10.1073/PNAS.75.4.1872
Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins.
W. Shen (1978)
10.1002/(SICI)1097-4636(199810)42:1<66::AID-JBM9>3.0.CO;2-M
Structure-property correlations in a combinatorial library of degradable biomaterials.
S. Brocchini (1998)
Synthesis and biological evaluation of immunoconjugates of adriamycin and human IgM linked by poly[N5-(2-hydroxyethyl)-L-glutamine]. J
C. Hoes (1996)
Influence of molecular size on passive tumour - accumulation of soluble macromolecular drug carriers
L. Seymour (1995)
10.1016/0006-291X(81)91644-2
cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate.
W. Shen (1981)
10.1016/0169-409X(91)90037-D
The therapeutic value of poly(ethylene glycol)-modified proteins
M. Nucci (1991)
10.1097/00001813-199206000-00001
Drug-polymer conjugates: potential for improved chemotherapy.
R. Duncan (1992)
10.1080/09553007214550361
Biological Aspects of Radiation Protection
J. V. Davies (1972)
Pharmaceutical uses of polymers : some recent developments
A. Florence (1974)
10.1016/0168-3659(95)00126-3
Synthesis and biological evaluation of immunoconjugates of adriamycin and a human IgM linked by poly[N5-(2-hydroxyethyl)-l-glutamine
C.J.T. Hoes (1996)
10.1002/jbm.820050307
Biological tolerance of poly(N-substituted methacrylamides).
L. Šprincl (1971)
10.1016/0169-409X(90)90017-M
Nanoparticles as microcarriers for anticancer drugs
P. Couvreur (1990)
10.1016/S0959-8049(97)00338-9
Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branched polypeptide.
D. Gaál (1998)
10.1002/MASY.19961030117
Polymeric prodrugs of mitomycin C
H. Soyez (1996)
Living radical polymerizations based on transition metal complexes
M. Sawamoto (1996)
10.1021/BC00023A600
Copolymers of lysine and polyethylene glycol: a new family of functionalized drug carriers.
A. Nathan (1993)
10.1038/NEWBIO239110A0
Chemotherapy through lysosomes with a DNA-daunorubicin complex.
A. Trouet (1972)
10.1002/1521-3773(20010202)40:3<594::AID-ANIE594>3.0.CO;2-P
Narrow Molecular Weight Distribution Precursors for Polymer-Drug Conjugates.
A. Godwin (2001)
10.1177/088391159000500102
Effect of the Chemical Modification of Dextran on the Degradation by Dextranase
R. Vercauteren (1990)
Drug delivery and targeting.
R. Langer (1998)
10.1517/14712598.1.4.583
Block copolymeric biotransport carriers as versatile vehicles for drug delivery
V. Alakhov (1998)
Anionic polyelectrolytes as antimitotic agents
W. Regelson (1968)
Solublemacromolecular carriers for delivery of antitumour agents
H. Sezaki (1989)
10.1002/1521-3927(20000801)21:12<853::AID-MARC853>3.0.CO;2-M
Synthesis of soluble polymers for medicine that degrade by intramolecular acid catalysis
M. Clochard (2000)
10.1080/10601329708010308
Mechanistic and synthetic aspects of atom transfer radical polymerization
K. Matyjaszewski (1997)
10.1016/0378-5173(95)00059-R
Alginates as drug carriers: covalent attachment of alginates to therapeutic agents containing primary amine groups
S. Morgan (1995)
10.1016/0169-409X(89)90013-6
Soluble macromolecular carriers for the delivery of antitumour drugs
H. Sezaki (1989)
10.1002/MASY.19860060112
Poly(organophosphazenes): synthesis, unique properties, and applications
H. Allcock (1986)
10.1002/MACP.1974.021750801
Pharmacologically active polymers, 7. Cyclophosphamide‐ and steroidhormone containing polymers as potential anticancer compounds
H. G. Batz (1974)
10.1016/0378-5173(95)00055-N
Synthesis, controlled release properties and antitumour activity of alginate-cis-aconityl-daunomycin conjugates
A. Al-Shamkhani (1995)
Chemical modification of proteins and polysaccharides and its effect on enzyme - catalysed degradation
W. Shalaby (1994)
Development of the aconityl degradable element for biomedical polymers
S. Simic (2000)
Cis-aconityl spacer between daunomycin
W. Shen (1981)
10.1016/S0928-0987(97)00069-9
Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption.
K. Abdellaoui (1998)
10.1021/JA01553A015
Intramolecular Catalysis of Hydrolytic Reactions. II. The Hydrolysis of Phthalamic Acid1,2
M. Bender (1958)
10.1016/0168-3659(92)90079-7
Carrier design: cytotoxicity and immunogenicity of synthetic branched polypeptides with poly(L-lysine) backbone
F. Hudecz (1992)
10.1021/JA970389Z
A Combinatorial Approach for Polymer Design
S. Brocchini (1997)
Influence of molecular size on
K. Ulbrich (1995)
Polymer drug conjugates : drug release from pendent linkers. In: Mathiowitz, E. (ed.) The Encyclopedia of Controlled Drug Delivery
S. Brocchini (1999)
10.1073/PNAS.85.4.1189
Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
H. M. Yang (1988)
Doxorubicin conjugate with a monoclonal antibody directed to a human melanoma - associated proteoglycan suppresses the growth of established tumor xenografts in nude mice
H. Yang (1988)
Lysosomotropic agents
C. deDuve (1974)
Targetable polymer drugs
K. Kataoka (1997)
10.1002/JBM.820100612
New types of synthetic infusion solutions. III. Elimination and retention of poly-[N-(2-hydroxypropyl)methacrylamide] in a test organism.
L. Šprincl (1976)
10.1021/JM9600555
Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms.
R. Greenwald (1996)
Pharmacologically active polymers 7
H. Batz (1974)
The role of polymer conjugates in the diagnosis and treatment of cancer
R. Duncan (1996)
Phase I clinical and pharmacokinetic study of PKI ( HPMA copolymer doxorubicin ) : first member of a new class of chemotherapeutic agents : drug – polymer conjugates
P. Vasey (1999)
Modulation of intratumoral drug delivery by the tumor microenvironment and vascular endothelial growth factor
W. Monsky (1998)
10.1007/BFB0024125
Polymer synthesis via activated esters: A new dimension of creativity in macromolecular chemistry
R. Arshady (1994)
POLYMER THERAPEUTICS FOR TUMOUR SPECIFIC DELIVERY
R. Duncan (1997)
10.1111/j.1349-7006.1998.tb00563.x
Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal Tissues
Youichiro Noguchi (1998)
Doxorubicin conjugate with a mono
H. Yang (1988)
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
F. Yuan (1995)
10.1016/0168-3659(90)90090-G
Synthesis and antitumor activity of conjugates of poly(α-malic acid) and 5-fluorouracils bound via ester, amide or carbamoyl bonds
T. Ouchi (1990)
10.1038/1871080A0
The Chemistry of Natural Products
R. J. W. L. Fèvre (1960)
10.1070/RC1974V043N01ABEH001789
Polymeric Chemotherapeutic Agents with Carcinolytic Activity
I. Iliev (1974)



This paper is referenced by
Synthesis and evaluation of some polymeric drug delivery systems.
J. Ravichandran (2010)
10.1002/ANIE.200502113
Polymer therapeutics: concepts and applications.
R. Haag (2006)
Prodrug approaches to reduce treprostinil toxicity
Christina Picken (2019)
10.4028/www.scientific.net/KEM.614.47
SEM Characterisation of a Tricalcium Phosphate – Chitosan - PMMA Cement
Hella Mahjoub (2014)
10.1007/s10570-019-02911-1
Correction to: Synthesis, characterization and ampyrone drug release behavior of magnetite nanoparticle/2,3-dialdehyde cellulose-6-phosphate composite
Sherif M. A. S. Keshk (2019)
10.1016/j.addr.2009.06.005
Design and development of polymer conjugates as anti-angiogenic agents.
E. Segal (2009)
DRUG DELIVERY: SPECIAL EMPHASIS GIVEN ON BIODEGRADABLE POLYMERS
Swati Aggarwal (2012)
10.1007/978-1-4419-8417-3_11
Liposomes and Polymers in Folate-Targeted Cancer Therapeutics
A. Gabizon (2011)
Untersuchungen zur zellulären Aufnahme von zellpenetrierenden Peptiden und der Bioaktivität von HPMA-Peptid-Konjugaten, sowie Charakterisierung eines neuen zellpenetrierenden Peptids aus humanem Lactoferrin
Falk Duchardt (2009)
EFFECT OF SOME POLYMERS USED IN PREPARATION OF TABLETS ON ABSORPTION OF ACTIVE INGREDIENTS Research Article
Allaham Antoun (2012)
Formulation and Evaluation of Aluminium Ion (Al +3 ) Cross-Linked Carboxymethyl Guar Gum Matrix Tablets For Colon Delivery
Vishram Yadav (2013)
10.2174/2211738504666160213001714
Polymer-drug nanoconjugate – an innovative nanomedicine: challenges and recent advancements in rational formulation design for effective delivery of poorly soluble drugs.
A. Abioye (2016)
10.1039/C6RA23557C
Norbornene derived nanocarrier reduces isoniazid mediated liver toxicity: assessment in HepG2 cell line and zebrafish model
T. Anju (2016)
10.1007/s10570-019-02887-y
Synthesis, characterization and ampyrone drug release behavior of magnetite nanoparticle/2,3-dialdehyde cellulose-6-phosphate composite
Sherif M. A. S. Keshk (2019)
10.1016/j.jconrel.2014.08.018
Imaging of doxorubicin release from theranostic macromolecular prodrugs via fluorescence resonance energy transfer.
H. R. Krüger (2014)
10.3390/pharmaceutics12020124
Polymers for Extrusion-Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective
M. A. Azad (2020)
10.1016/j.jconrel.2011.01.017
Development of efficient acid cleavable multifunctional prodrugs derived from dendritic polyglycerol with a poly(ethylene glycol) shell.
M. Calderón (2011)
10.1002/ANGE.200502113
Polymere Therapeutika: Konzepte und Anwendungen
R. Haag (2006)
10.1021/acs.joc.6b01593
Enhanced Glutathione Peroxidase Activity of Water-Soluble and Polyethylene Glycol-Supported Selenides, Related Spirodioxyselenuranes, and Pincer Selenuranes.
Nicole M R McNeil (2016)
10.1081/E-EBPP-120050043
Conjugates, Polymer–Drug: Polymer–Protein Drug Delivery
Harmeet Kaur (2015)
10.1007/978-1-4614-7876-8_19
Targeting Drugs to Cancer: A Tough Journey to the Tumor Cell
Shiran Ferber (2013)
ROLE OF BIODEGRADABLE POLYMERS IN DRUG DELIVERY
J. Joshi (2012)
10.1016/j.jconrel.2011.12.021
Administration, distribution, metabolism and elimination of polymer therapeutics.
Ela Markovsky (2012)
10.1016/J.CARBPOL.2011.06.008
Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and all-trans-retinoid acid
L. Hou (2011)
10.1016/B978-1-78242-105-4.00003-1
Biodegradable and bioerodible polymers for medical applications
K. Uhrich (2016)
10.1007/s10904-012-9697-5
Polystyrene Containing Carbinolamine/Azomethine Potentially Useful as Antimicrobial Agent: Synthesis and Biological Evaluation
Esra Bozkır (2012)
Polymers for Colon Targeted Drug Delivery: A Review
S. Neha (2013)
10.2217/fon-2020-0198
Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress.
Harshita Abul Barkat (2020)
10.1016/j.biochi.2010.02.017
Functional dendritic polymer architectures as stimuli-responsive nanocarriers.
M. Calderón (2010)
10.1002/IJCH.201000020
Rational Design of Multifunctional Polymer Therapeutics for Cancer Theranostics
P. Ofek (2010)
10.1002/9783527800681.CH10
Nanopharmacy: Exploratory Methods for Polymeric Materials
K. K. Bansal (2016)
10.1002/chem.201800182
Cyclic Seleninate Esters, Spirodioxyselenuranes and Related Compounds: New Classes of Biological Antioxidants That Emulate Glutathione Peroxidase.
Kai N Sands (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar